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Abstract: Protection against chronic infections has necessitated the development of ever-more
potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly
immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system.
Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell
responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses.
Here, we review the emerging concept of merging these two technologies into virus-like-vaccines
(VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect
cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors
and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust
particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and
immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors
and we have developed the concept into a single-reading adenovirus-based technology capable of
eliciting robust CD8+ and CD4+ T cells responses and trimer binding antibody responses. Such
vaccines offer the potential to display the naturally produced immunogen directly and induce an
integrated humoral and cellular immune response.
Keywords: virus vectors; virus-like-particles; T cells; antibodies; HIV; virus-like-vaccines
1. Introduction
HIV and, in particular, HIV-1, is one of the most important challenges to vaccine research as
it evades both antibody and T cell responses and is a major global health problem, with close to
2 million annual fatalities [1]. Despite the continued absence of a marketed vaccine against either
HIV-1 or HIV-2, clinical trials and non-human primate studies have suggested that meaningful levels
of protection may be achievable [2,3]. With success apparently just out of reach, the development of
a vaccine against HIV-1—which is the most studied of the two HIVs (94,000 vs. 5900 pubmed hits
for HIV-2) and the only one discussed in this review—has been the inspiration for much research in
vaccine technology, resulting in improved tools for induction of both T cell and antibody responses.
Despite these important advances, live-attenuated vaccines developed more than two decades ago [4]
and attenuated natural infection [5] remain the only successful approaches against virulent simian
HIV homologues.
There are many reasons for the failure to develop a viable HIV vaccine, but the diversity of the
circulating HIV-1 strains, high mutation rate, and rapid seeding of intracellular DNA reservoirs, which
can be invisible to the immune system, are key challenges [6].
Live-attenuated vaccines are successful, at least in part, because they maintain an activated
cellular response at mucosal surfaces and mucosa draining lymph nodes, which can prevent seeding
of a latent reservoir [7,8]. By being rapidly effective, they also prevent the generation of viral
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diversity, which would fuel subsequent immune escape. Antibody-inducing vaccines could do
the same if they were effective during, or immediately following, infection and effector T cells can,
as demonstrated, prevent virus spread and contain infection. However, T cells may be difficult
to maintain in sufficient numbers and activation state, which points to a combined antibody- and T
cell-inducing vaccine as a more realistic option [9]. But how can such an immune response be obtained?
During natural acute infections with most agents (e.g., Measles), antiviral defense triggers effector
mechanisms and induces life-long protective immunity following the elimination of the infection [10].
Prominent immune-mediated effector mechanisms following such an outcome are cytotoxic T cells and
neutralizing antibodies, the latter being the most desired correlate of protective immunity. In HIV, the
T cell response and the neutralizing antibodies arrive too late, but the demonstration of experimental
efficacy by live-attenuated vaccines remains a beacon of hope in HIV vaccine research [4]. As explained,
live-attenuated viral vaccines that mimic many aspects of resolved acute infection are among the most
effective tools available today. However, against HIV they are considered too dangerous, and further
decreasing virulence may not be possible as this would negatively affect vaccine immunogenicity
and the duration of an effective memory response [11]. On the other hand, virus-like-particle (VLP)
vaccines, appear to offer many of the same desirable properties as live-attenuated vaccines [12]. VLPs
allow the exhibition of viral antigens on a viral surface, similar to live-attenuated vaccines, with one
example being the Human Papilloma Virus (HPV) vaccines based on self-assembling papillomavirus L1
capsid proteins [13]. Whereas the HPV vaccines induce protective neutralizing antibody responses and
have been translated into commercial and medical success stories, VLP-based vaccines have failed to
induce protection against other diseases [14]. A notable difference between such ex vivo VLPs, natural
infection, and live-attenuated vaccines, is the absence of de novo synthesis of viral antigens in vivo
and, thus, only minor cytotoxic T cell responses. This is important to note as the major remaining
challenges for antiviral vaccine research can all be defined as those where a relevant high-titered
neutralizing antibody response cannot easily be induced. In contrast, natural immunity to infection
seems to be related to the induction of protective T cell responses [15]. Therefore, a vaccine that could
elicit antibodies as efficiently as VLP vaccines and simultaneously induce cytotoxic T cells could bridge
natural and artificial immunity. Such vaccines can be generated by simply moving VLP production
from the factory and into the vaccinee using vectored or virus-encoded VLP-based vaccines [16].
Replication-defective viral vectors encoding the machinery for producing virus particles allow such
experimental vaccines to capture the essentials of a viral infection and subsequent release of VLPs. This
review is dedicated to explaining how in vivo synthesized VLPs, here defined as virus-like-vaccines
(VLVs) can be designed, how they compare to their parent designs VLPs and virus vectored vaccines
(Figure 1, VLV principle), and, in particular, their potential in targeting HIV.
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Figure 1. Primary immunological mechanisms of virus vectored-, VLP-, and VLV-induced antigen 
presentation. The top panel depicts a virus vectored vaccine that encodes an intracellular or non-
secreted antigen. The principle manner of antigen presentation is via MHC class I presentation to 
CD8+ T cells through the direct presentation pathway. The middle panel depicts a classical ex vivo 
purified and injected VLP vaccine, which can be taken up by antigen-presenting cells to be presented 
on MHC class II and stimulate CD4+ T cells, and directly stimulates B cells with antigen in the form 
of VLPs. The bottom panel depicts a VLV, where the antigen is initially synthesized intracellularly for 
MHC class I presentation, followed by the release of VLPs, which stimulate CD4+ T cells and B cells, 
as in the middle panel. 
2. Immunological Differences between VLPs and VLVs 
VLPs are highly attractive vaccine vehicles, as evidenced by their success in targeting 
papillomaviruses and Hepatitis B virus [12]. Initially used for homologous disease targeting, the 
design of chimeric VLPs has enabled the combination of non-naturally associated VLP antigens and 
heterologous VLP antigens to be genetically fused, “glued”, or chemically coupled to VLP vehicles 
[17]. The superiority of VLP-exhibited antigens, compared to antigens alone, has been shown in 
numerous studies [18–20]. For stable and simple antigens VLP antigen delivery is straightforward, 
with a direct translation into effective triggering of B and CD4+ T cell responses. Claims that VLPs 
can trigger CD8+ T cell responses are abundant in the scientific literature [21], but direct comparisons 
with other methods that excel in CD8+ T cell induction are scarce. Indeed, while VLPs improve CD4+ 
T cell and antibody responses, VLP incorporation is inferior to, and has no added effect on top of 
viral vector-encoded antigens [22]. This is not meant to claim that VLPs do not induce CD8+ T cells at 
all, as such responses are frequently detectable, but that there are much better ways to induce 
cytotoxic T cells by vaccination.  
VLVs are simply VLPs encoded within a replication deficient viral vector. Upon vaccination, the 
viral vector infects antigen presenting cells (APCs) to induce direct antigen presentation of the 
encoded antigen on MHC class I, leading to the triggering of CD8+ T cells [23]. Next, the infected 
APCs produce VLPs, which are secreted and can be presented to dendritic cells and B cells for further 
triggering of CD4+ T cells, CD8+ T cells, and antibody responses [16,23]. Compared to VLVs, VLPs 
generally contain scant genetic material and only induce limited innate immune activation, but can 
be engineered to increase such activation by including TLR ligands or other adjuvants [24]. 
Compared to DNA-encoded VLPs, viral delivery differs in the induction of more innate 
inflammation, the efficient direct targeting of dendritic cells, and the delivery of excess vector-derived 
antigen, which may contain helper T cell epitopes. The latter, admittedly, comes with a caveat, as 
these vector epitopes are also generally off-target with regard to the desired vaccine-induced 
protection (discussed in detail in Fougeroux et al. [25]). Overall, several key properties of individual 
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generally off-target with regard to the desired vaccine-induced protection (discussed in detail in
Fougeroux et al. [25]). Overall, several key properties of individual types of VLVs, including strengths
and limitations, follow the vector type used to encode VLPs, but there are differences during repeated
administration that will be discussed in the following sections [26,27].
Another important difference between VLVs and VLPs is that VLPs require stability of both
particles and surface antigens, both with an acceptable shelf-life. VLVs only require that the delivery
vehicle is producible and stable, that the actual appropriately folded immunogenic antigens are
produced in situ, and that the recombinant antigen does not need much stability, as it does not require
any kind of storage.
3. Poxviral Vectors Encoding HIV and SIV VLPs
Natural immunity and vaccine immune correlates of protection against HIV are not well defined
and will be discussed in more detail in separate sections below. However, in very broad terms, control
of natural HIV infection is clearly T cell-mediated [15] and artificial immunity can clearly be provided
by antibodies [28]. For these reasons, it has been natural for us to develop vaccines against HIV with
encoded delivery platforms capable of mobilizing both arms of the immune system. The first VLV
designed to target HIV encoded inactivated HIV or SIV genomes in vaccinia or modified vaccinia
Ankara vectors (MVA) [29]. This was possible because poxviral vectors are intrinsically capable of
delivering large transgenic sequences. By deleting parts of the genes, viruses were made which
encoded the majority of HIV and were, indeed, capable of secreting VLPs [30]. These vaccines are
among the most successful pre-clinical vaccine candidates targeting HIV. When tested in human trials
they induced non-neutralizing antibody responses not unlike those that elicit partial protection in
non-human primate models of HIV infection [30]. Notably, a later designed recombinant canarypox
vector expressing HIV Gag and protease from clade B, and gp120 of clade E fused to the transmembrane
portion of HIV Env from clade B, in effect dangling gp120 monomers secreted on Gag-based VLPs,
was the priming vaccine in the now famous RV144 trial in Thailand, where partial protection was
induced against HIV [2].
Unfortunately, while MVA vaccines, even without a DNA prime, are excellent antibody and CD4+
T cell response inducers, they are not the principal inducers of CD8+ T cells [31]. In contrast, adenovirus
vaccines are excellent inducers of CD8+ T cells and antibodies. Hence, it is not surprising that the
combination of adenovirus and MVA in prime-boost regimens is among the most potent immunization
regimens tried in humans or non-human primate (NHP) models [3,32,33]. This realization provided
our rationale for designing a VLV based on adenovirus vectors, with the initial aim to combine such
adenoviral vaccines with already available vaccines based on MVA.
4. A Simplified Approach to the Generation of Adenovirus-based VLVs
Compared to poxviruses, first-generation adenoviruses have a more limited cloning capacity of
4–8 kilobases, which necessitates a simplified expression cassette. In order to encode the necessary
lentiviral elements, we used the self-cleavable P2A sequence, derived from Porcine Teschovirus, and
encoded gag, followed by P2A, then envelope (Env) (see Figure 2 and Andersson et al. [16]). We did
this realizing that the 1:1 stoichiometry provided by the P2A sequence would produce Env in excess of
requirements, but previous reports have also suggested that self-surface expressed Env may contribute
to immune responses [34]. More troublesome were the reports of past difficulties in making MVA
express full length Env, which demonstrated selection for truncations in the cytoplasmic tail of Env
during vector propagation [35]. Indeed, the first MVA vaccines encoding HIV and SIV uniformly
contained truncations in the cytoplasmic tail of the HIV Env proteins. These truncations were,
nevertheless, beneficial for antigen incorporation into VLPs, but with then-unknown consequences for
antigenicity [36]. Adenoviruses are known to suffer from the same propagation limitations of certain
genes and antigens; however, Cottingham et al. demonstrated that tetracycline repressor-dependent
reduction of transgene expression could rescue vectors that were otherwise difficult to produce [37].
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Accordingly, a similar system was used to rescue viruses with the intended full-length env gene [16]
that were clearly capable of producing massive amounts of VLPs in cell types non-permissive for
adenovirus replication (see Figure 3 and Andersson et al. [16]).Vaccines 2018, 6, x  5 of 16 
 
 
Figure 2. Design of the single frame transgenic cassette in adenoviral VLVs. The viral VLP-forming 
Gag protein is synthesized in-frame with the Env antigen, but separated with a self-cleavable peptide. 
This produces Gag and Env or any other downstream antigen in a 1:1 ratio. 
 
Figure 3. Secretion of VLPs from vector transduced cells. Vero cells infected with VLVs, then fixed, 
embedded, sectioned, and stained for transmission electron microscopy. The right-side micrographs 
depict higher magnification of the overview images to the left. The scale bar is visible at the lower 
right of the bottom micrographs. Specific experimental conditions were as described in Andersson et 
al. 2016 [7].  
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The inability of the former MVA vectors to propagate a full-length cytoplasmic tail, coupled with 
published reports on VLP antigen density as a primary determinant of responses against difficult 
antigens [38], made it logical to study the relation between tail truncations and induced immune 
responses. Full-length and truncated Env were packaged into SIV Gag-based VLPs, and used as a 
priming VLVs, before boosting with heterologous adenovirus vectors expressing the full-length Env 
on VLPs [16]. The immediate consequence of the Env tail truncation was that the Env cell surface 
display increased dramatically and Env incorporation into VLPs increased moderately. Additionally, 
the displayed Env conformation became much more accessible to non-neutralizing specificities like 
Figure 2. Design of the single frame transgenic cassette in adenoviral VLVs. The viral VLP-forming
Gag protein is synthesized in-frame with the Env antigen, but separated with a self-cleavable peptide.
This produces Gag and Env or any other downstream antigen in a 1:1 ratio.
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5. Adenovirus Vectored VLVs Targeting HIV, SIV, and P. falciparum
The inability of the former MVA vectors to propagate a full-length cytoplasmic tail, coupled with
published reports on VLP antigen density as a primary determinant of responses against difficult
antigens [38], made it logical to study the relation between tail truncations and induced immune
responses. Full-length and truncated Env were packaged into SIV Gag-based VLPs, and used as a
priming VLVs, before boosting with heterologous adenovirus vectors expressing the full-length Env on
VLPs [16]. The immediate consequence of the Env tail truncation was that the Env cell surface display
increased dramatically and Env incorporation into VLPs increased moderately. Additionally, the
displayed Env conformation became much more accessible to non-neutralizing specificities like those
detected with the 17b monoclonal antibody [39]. In fact, even with an increase of up to approximately
40-fold on the cell surface, which could be detected with the 17b or VRC01 monoclonal antibodies,
increased binding of the conformation-specific antibodies, PGT145 and PGT151, that require a tightly
folded trimer, was not observed [40]. In this light, it is perhaps not surprising that immunization with
the truncated version resulted in a significantly stronger antibody response towards the recombinant
gp140CFI protein, which is not a tightly folded antigen, and only a small, barely significant increase
in binding to trimeric Env purified from VLPs [16]. Conversely, priming with a full-length tail gave
responses that trended towards an increased gp41 response and the ratio of gp120/41 binding responses
was significantly higher in the truncated tail group [16]. The dramatic changes in Env conformation
were consistent with recent results in transfected cells [36] but it makes interpretation of the effects of
Env incorporation into VLVs quite difficult. Superficially, one would not think that an excess antigen
load, solely consisting of incompletely folded Env, would be beneficial, but this may be a wrong
prejudice, as the RV144 trial primed with a poxvirus-delivered VLV essentially must have displayed
a gp120 monomer dangling from the VLPs [41]. That the full-length antigen group trended toward
higher gp41 responses is interesting, but the mechanism is not known and neither is the significance.
One could imagine both reduced steric constraints (illustrated in Figure 4) and reduced competition
from the many more accessible gp120 epitopes in the truncated constructs. Certainly, access to epitopes
is important as we, in an unpublished cohort, also tested fully transmembrane deleted gp140CFI,
which is secreted unbound to the encoded VLPs and which did elicit higher responses towards gp41
(Andersson et al. unpublished). Likely, a part of this response could be mediated by antibodies
approaching the gp41 from angles that would be from within the VLPs in the constructs containing
the TM region.
An alternative to binding antibodies would be to look at neutralization, but neither of the VLVs
tested in Andersson et al. [16] neutralized tier 2 viruses, and, while neutralization was induced against
tier 1 viruses, the different vaccines used for priming did not result in significantly different tier
1 neutralization titers. Unfortunately, transmitted viruses are, for the most part, tier 2 viruses and, thus,
the readout can only tell us that we would not be able to neutralize HIV with the kind of responses we
obtained in mice. The absence of tier 2 neutralization can be seen as disappointing in comparison to
emerging data in the field, but that would be a gross misinterpretation. The response types now known
to be inducible by SOSIP BG505 and related to more consistently folded trimeric Env antigens, is
limited to autologous responses and highly restricted towards other types [42]. Indeed, these responses
typically target rare defects in Env glycosylation or linear non-conserved epitopes [43,44]. While these
constructs have clearly solidified our knowledge of the challenges faced in HIV vaccine design, they
have provided no clear path forward. Indeed, the focus on obtaining tier 2 virus neutralization may be
detrimental, as this draws resources and focus from DNA and virus vectored regimens that, while not
able to yield the same consistency in autologous tier 2 neutralization, can provide broader binding
antibody responses [45]. Currently, the only inducible mechanism of protection we know of with
some certainty is that protection against HIV acquisition can be elicited by broadly cross-reacting
antibodies [46].
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Env is depicted with gp120 in light brown and the visible parts of gp41 containing the transmembrane
region in dark blue. In the middle drawing, VLPs, scarcely coated with Env, can be seen to be
approachable from all angles. Dense coating of the VLPs, as depicted in the right drawing, makes
gp120 more accessible relative to gp41.
The inability to provide a qualified interpretation regarding the expected efficacy of VLVs
generated with full-length and truncated Env displaying VLPs, is typical of the current status of
the HIV field. We know that particular flavors of antibodies predicted short-term protection in the
RV144 trial, but also that non-human primates respond with different specificities to HIV Env vaccines
than humans. This has been demonstrated by simianized vaccines, in which an SIV Env and Gag
replaces the HIV sequences in vaccines otherwise identical to the RV144 trial [47]. Nevertheless,
these simianized vaccines seem to induce protection against repeated low dose challenges, just as
the RV144 trial [48]. Currently, no one knows what the inbred or outbred murine counterpart is of
the poorly understood human correlates of protection and it is possible that, rather than specific
correlates, functional correlates would translate better between species [49,50]. At present, this is
largely speculative and what is really needed is qualified testing in non-human primate models. Such
tests have not been a realistic option in the past for HIV, but would now be possible to perform with
increased accuracy as a new generation of Simian Human Immunodeficiency Viruses (SHIVs), with
transmitted founder-like Env sequences, has become available [51].
While the tail truncation succeeded in increasing VLP incorporation as desired, it changed the
antigenicity to a large degree. For that reason it could not be answered how the antigen density on
particles influenced specificity, quantity, and avidity of responses on an enveloped virus-encoded
retroviral VLP. To address this question, we made similar designs of a P. falciparum derived antigen
VAR2CSA, that is a Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP1) family member.
VAR2CSA is necessary for the adhesion to placental chondroitin sulfate A, and, thereby, to cause
pregnancy-associated malaria [52]. PfEMP1s are assembled from modular domains and, thus, provided
the opportunity to use an efficient folding and ligand binding protein not likely to be dependent
on signals in the intracellular tail for correct folding [53]. This antigen was directed into the ER
using a synthetic signal peptide and anchored with either a mouse mammary tumor virus envelope
tail, an influenza A hemagglutinin tail, or was left non-anchored for secretion of antigen [52]. The
results were quite clear in that VLP incorporation improved the quantity of the responses after single
administration and the functionality of the responses remained superior in the VLP designs after
repeated protein boosting. It was also encouraging to notice that the hemagglutinin tail provided
better incorporation into VLPs, which was paralleled by more functional responses after adenovirus
VLV immunization, as compared with the less efficiently incorporated mouse mammary tumor virus
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envelope tail. Interestingly, a peptide array used to measure responses against linear B cell epitopes
showed more specificities targeted with the hemagglutinin tail anchored antigen [52]. While these data
are a poor substitute for an HIV-specific response, they are in agreement with similar studies using
DNA-encoded VLPs, which do elicit more potent responses towards VLP-displayed Env, compared
to membrane-anchored Env with the same Env sequence [20]. The results, using peptide arrays,
also suggested a potential basic mechanism: that efficient VLP incorporation could trigger a more
functional and broader response against the displayed antigen [52]. The latter interpretation is also
in agreement with other studies showing that VLP incorporation alters the specificity of the induced
antibody response [54] and that intrastructural help from T cells specific for VLP proteins, increases
the ability of the antibodies to elicit Fc receptor-mediated effector functions [55]. Interesting correlates
aside, we currently do not know to what extent protective non-neutralizing antibody responses target
the closed conformation of transmitted founders with tier 2 characteristics in vivo or if they, as an
alternative example, trigger antibody-dependent cell-mediated cytotoxicity (ADCC) via binding to a
subset of misfolded proteins on cell surfaces or virions. Ideally, it should be possible to change the
incorporation level of Env without altering antigenicity and, thereby, induce stronger and broader
responses against the presumed most relevant Env conformation for tests in primate models. Vaccines
with enhanced VLP incorporation, displaying the most relevant closed trimer conformation, could
then be compared with vaccines expressing Env with truncated tail conformations for immunogenicity
and protection in non-human primate models. Such an experiment could potentially be envisaged
using non-native tails, as in our VAR2CSA vaccine, and these tails could be used to display stabilized
transmitted founder-like Env proteins, such as BG505 based NFL trimers [56].
6. Suggested Mechanisms of Antibody-Mediated Protection from SIV, SHIV, or HIV Infection
Only stable trimers, that to a large degree avoid displaying non-neutralizing epitopes associated
with open Env conformations, seem capable of inducing tier 2 virus neutralizing antibodies [42].
However, the RV144 trial induced protection, seemingly, via cross-reacting, but non-neutralizing V1V2
antibodies capable of eliciting ADCC. Additionally, the high avidity of Env trimer binding antibodies
induced by MVA VLVs, is a protective correlate in SIV and SHIV challenge models [48,57]. The
battle between the quest for neutralization and for probing deeper into non-neutralizing antibodies is,
however, still unresolved. Certainly, it must be acknowledged that non-neutralizing antibodies, by
themselves, are not very efficient [58], but, then again, otherwise protective recombinant Env protein
immunogens that are very poor T cell inducers have been able to induce cross-protective antibodies in
animal models, even though such immunity was not transferable by serum from protected animals [59].
The question of antibody localization comes to mind and mucosal antibodies have, indeed, been
correlated with protection from SIV [60]. Many studies have also found correlates of protection with
antibodies neutralizing tier 1 viruses and so-called “sieve” analysis, which compares neutralization
sensitivity of pre-challenge viral swarms with transmitted viruses, also points to neutralization as a
key determinant of partial efficacy [61]. These latter types of studies are, however, prone to erroneous
conclusions for this particular question, as non-neutralizing antibodies, per definition, bind open
conformations that are shielded in neutralization resistant viruses [62].
7. VLV Induced Antibodies in Prime-Boost Regimens
One of the most impressive findings in this era of heterologous prime-boost regimens, has been
the observation of consistent induction of Env trimer binding antibodies in animals vaccinated three
times with homologous MVA vectored VLVs. Such protection is, as highlighted above, correlated with
high avidity antibodies towards Env and not T cell responses, and although the specificity is changed
to gp41, similarly highly avid antibody responses can be induced in healthy human volunteers [30].
To substantiate the point that protection in this system is antibody mediated, the T cell response
towards the MVA vaccines is rather limited, and reducing the T cell response further in vaccinia virus
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immune animals [63] or increasing it by DNA prime [64], has no effect on post-exposure control of
viremia that cannot be explained by differences in the antibody response.
The robust induction of antibody responses towards MVA VLVs stand in contrast to a recent
trial using BG505 Env sequences in MVA vectors in rabbits, where the induction of Env trimer
binding antibodies was unreliable, and generally much inferior to repeated recombinant protein or
adenovirus vector immunization, which yielded robust responses even after the first immunization [45].
Importantly, combinations of adenovirus prime and MVA boost yielded potent responses after the
first booster immunization, in agreement with numerous other studies. This recent study could be
interpreted to indicate that VLVs based on an HIV Env and Gag are superior in a single formulation;
however, it must be emphasized that the differences can also be attributed to the different Env antigen
(BG505) [45] vs. SIV mac239 [23,64] vs. HIV clade B [16,65], and not just the existence of a VLP in the
SIV and HIV clade B VLV studies [65].
In summary, VLVs seem, at least, competitive and, perhaps, superior for the induction of antibody
responses compared to secreted formulations [52], but it has been hard to substantiate superiority in
the HIV field, where the antigenicity of Env is highly affected by the strain of the antigen and the
exact formulation of the VLV. Indeed, we do not know what a good and realistic antibody response
is. Controlled trials against realistic SHIV models with transmitted founder-like Env sequences are
urgently needed.
8. VLVs as Inducers of T Cell Responses
While the MVA VLVs mentioned above [57,65]—in contrast to the non-VLV MVA expressing
BG505 Env [45]—are efficient inducers of trimer binding antibodies, they are poor T cell inducers [64].
In agreement with other studies, MVA VLVs need DNA priming [64] or, ideally, another viral
priming [45], to facilitate competitiveness of the transgene product with vector derived products [66].
Replication-defective adenovirus vectors, in contrast, are capable inducers of T cell responses
against a number of transgenes, as the commonly used E1 deletion reduces the expression of vector
proteins outside the viral producer cells [25,67]. In combination with MVA used as a booster
vaccination, the adenovirus primed T cell responses have given rise to some of the most impressive T
cell frequencies in both human and animal models [3,33]. Adenovirus-primed and, in particular,
adenovirus-boosted T cell responses against the structural Gag antigen do not seem capable of
preventing any fraction of HIV/SIV infections, but they are clearly the most validated cells for
post-acquisition control of SIV infection [32,68]. Even in the human STEP trial, which failed in its
overall objectives, those vaccinees who succeeded in raising multiple T cell responses towards Gag
had significant and long-term reductions of viremia [69].
In NHP studies, a number of T cell correlates have been proposed and it seems efficacy in
controlling infection is more a matter of inducing the right specificities than inducing many specificities.
Obviously, a broad response will be more likely to include protective epitopes, but it is important to
realize that many T cell responses are without any inhibitory impact on viral replication. Vaccination
exclusively against protection-associated epitopes, compared to vaccination exclusively against
non-protection-associated epitopes, showed that the epitopes not associated with long-term protection
were completely without effect, even though they could induce responses of equal magnitude [70].
This kind of effect can potentially be related to the ability of mutations, in such epitopes, to confer a
replicative penalty on the virus, as suggested in human correlative studies [71].
SIV VLVs have been used in an attempt to induce an immune response focused on the conserved
elements (CEs) of Gag, by varying the origin of the Gag sequence (HIV and SIV mac239) between
prime and boost immunization [23]. This was done with the a priori hypothesis that a heterologous
Gag sequence would boost conserved epitopes selectively, but, rather surprisingly, changing the
Gag sequences between an adenoviral VLV prime and a MVA VLV boost diminished boosting of
Gag-specific responses and resulted in immunodominance of the SIV Env sequence that was shared in
the prime and boost vector. In contrast, animals boosted with the same SIV Gag in the adenovirus and
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MVA VLVs exhibited very strong SIV Gag-specific responses, which were superior to the heterologous
Gag group, both within the cross-reactive CE-specific responses and overall (see schematic outlining the
apparent outcome in Figure 5). Thus, from the perspective of a normal vaccine design, the heterologous
VLV design did everything it was supposed to do, except enabling the selective stimulation of
cross-reactive epitopes between the prime and boost immunization. These results differ from a
number of other studies in the field, in both mice and humans [72–74]. Thus, Barouch and co-workers
did not find any appreciable differences between consensus and a circulating HIV clade in prime-boost
regimens, but in these studies no Env was encoded, and the differences between the Gag sequences
were in the same 90% similarity range, where we generally observe reliable cross-reactivity [72,75].
Conversely, the human studies using either Env or Gag of more than 10% sequence diversity have,
indeed, elicited improved cross-reactive responses [73,74], suggesting that our experiment could
have worked, if not for the immunodominance exhibited by the homologous Env sequence in our
study [23]. At first glance, the critical role of immunodominance hierarchies during prime-boost VLV
immunization regimens may appear to be a limitation of the VLV design, but it is also an opportunity.
HIV Envs are considerably more diverse than the corresponding Gag sequences, and it should be
possible to design prime-boost regimens with more diversity in the Env than in the Gag component
of VLVs. Furthermore, for eliciting immune responses matching protective correlates against HIV,
we are interested in combining cross-reactive antibody responses against Env, cross-reactive T cell
responses against Gag, and, potentially, other conserved epitopes residing in the structural genes [76].
Importantly, T cells do not, in general, appear to exert immunodominance over Env-specific antibody
responses, rather both CD4+ and CD8+ T cells enhance antibody responses through a phenomenon
called intrastructural help [55,77]. In Andersson et al. [23], a similar positive correlation was observed
between the CD8+ T cell response towards Gag in the homologous Gag group and the CD8+ T cell
response towards Env in the heterologous Gag group [23]. The phenomenon of concomitant T cell
immunodominance and assistance towards antibody responses could also have been responsible
for the previously reported increased response towards MVA VLVs in MVA-immune animals. Here,
transgene-specific cellular responses were seen to be blunted (presumably by vector-specific immunity),
but antibody responses and, in particular, their functionality were increased [63].
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prime and boost, but the proof of this potential vaccination protocol awaits ongoing studies. One of
the key uncertainties that have become apparent from attempts to elicit cross-reactive T cells from
heterologous insert prime-boost VLVs, is whether avoiding competition is sufficient to select for the
desired specificities. The sequences associated with protection from HIV are also selected through
evolution to be poorly immunogenic in the most common human haplotypes [78,79]. Evidence suggests
that conserved elements can be primed by DNA and then boosted with full-length Gag sequences
encoded in adenoviral vectors, but such an approach adds yet another layer of complexity to a future
HIV vaccine [80]. If it is possible to express similar concatenated epitopes, either by co-encoding them
or inserting them in the VLPs encoded by viral vectors, and raise immune responses to such epitopes,
is presently unknown. Viral vectors hold several advantages over the tested DNA vaccines, particular
with regard to immune potency, but they do come with a number of viral epitopes that can exert
immunodominance over subdominant epitopes [81,82]. Alternatives also exist by looking at other viral
genes, such as nef and pol, where there are conserved epitopes, of which some are protection-associated;
however, Nef is quite variable over most of the sequence and Pol is likely to be less immunogenic at
low viral replication levels [83,84]. Therefore, a response to such conserved epitopes might be easier
to induce than a response to the conserved epitopes embedded in Gag; although, to insert them into
vaccines would also run the risk that they are less effective in controlling virus replication to low levels.
If these issues could be adequately resolved in future works, VLVs would be capable of inducing
broad binding antibody responses, potent T cell responses, and selection for recognition of structurally
conserved epitopes. Such properties summarize the current knowledge on natural and vaccine
inducible immunity towards HIV and show that the test of such a vaccine would be a highly
relevant experiment.
9. Conclusions
Virus-like-vaccines are virus vectored vaccines that infect APCs and tissue resident cells to initiate
strong cellular immune responses, and then lead to the secretion of virus-like-particles within the
vaccine recipient. This enables the production of structurally relevant antigens to stimulate B cells
and provides extracellular antigens in an inflammatory milieu to stimulate helper T cells and further
CD8+ T cell responses through cross-presentation. VLVs are potent vaccination tools because they
deliver the antigen in the form to which the immune system is developed to react. Current experience
has provided the best results against HIV using a VLV [2] and a new category of VLVs are capable of
reproducing the currently available correlates of vaccine protection against HIV in animals [23,48].
Acknowledgments: The current manuscript summarizes and places into context the vaccine development
conducted by Anne-Marie C. Andersson during her PhD project, which was funded by the Lundbeck Foundation.
The authors especially wish to thank Bang Thi Tuyet Nguyen for providing the drawings.
Author Contributions: Anne-Marie C. Andersson and Peter J. Holst wrote the paper with editing, and
contributions to the perspective, by Melanie Schwerdtfeger.
Conflicts of Interest: Peter J. Holst is the founder of InProTher ApS which holds licensing rights to virus vectored
vaccines against cancer, papillomavirus, and HIV. There are no specific rights granted to the virus-like-vaccines
concept within HIV. The other authors declare that no conflict of interest exists. The founding sponsors had no role
in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript;
and in the decision to publish the results.
References
1. Wang, H.; Wolock, T.M.; Carter, A.; Nguyen, G.; Kyu, H.H.; Gakidou, E.; Hay, S.I.; Mills, E.J.; Trickey, A.;
Msemburi, W.; et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV,
1980–2015: The Global Burden of Disease Study 2015. Lancet HIV 2016, 3, e361–e387. [CrossRef]
2. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.;
Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1
infection in Thailand. N. Engl. J. Med. 2009, 361, 2209–2220. [CrossRef] [PubMed]
Vaccines 2018, 6, 10 12 of 17
3. Liu, J.; O’Brien, K.L.; Lynch, D.M.; Simmons, N.L.; La, P.A.; Riggs, A.M.; Abbink, P.; Coffey, R.T.;
Grandpre, L.E.; Seaman, M.S.; et al. Immune control of an SIV challenge by a T-cell-based vaccine in
rhesus monkeys. Nature 2009, 457, 87–91. [CrossRef] [PubMed]
4. Daniel, M.D.; Kirchhoff, F.; Czajak, S.C.; Sehgal, P.K.; Desrosiers, R.C. Protective effects of a live attenuated
SIV vaccine with a deletion in the nef gene. Science 1992, 258, 1938–1941. [CrossRef] [PubMed]
5. Lifson, J.D.; Rossio, J.L.; Piatak, M., Jr.; Parks, T.; Li, L.; Kiser, R.; Coalter, V.; Fisher, B.; Flynn, B.M.; Czajak, S.;
et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to
rechallenge after transient early antiretroviral treatment. J. Virol. 2001, 75, 10187–10199. [CrossRef] [PubMed]
6. Haynes, B.F.; Shaw, G.M.; Korber, B.; Kelsoe, G.; Sodroski, J.; Hahn, B.H.; Borrow, P.; McMichael, A.J.
HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe 2016, 19, 292–303. [CrossRef]
[PubMed]
7. Fukazawa, Y.; Lum, R.; Okoye, A.A.; Park, H.; Matsuda, K.; Bae, J.Y.; Hagen, S.I.; Shoemaker, R.; Deleage, C.;
Lucero, C.; et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus
infection in elite controllers. Nat. Med. 2015, 21, 132–139. [CrossRef] [PubMed]
8. Fukazawa, Y.; Park, H.; Cameron, M.J.; Lefebvre, F.; Lum, R.; Coombes, N.; Mahyari, E.; Hagen, S.I.; Bae, J.Y.;
Reyes, M.D., III; et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines.
Nat. Med. 2012, 18, 1673–1681. [CrossRef] [PubMed]
9. Williamson, A.L.; Rybicki, E.P. Justification for the inclusion of Gag in HIV vaccine candidates. Expert Rev.
Vaccines 2016, 15, 585–598. [CrossRef] [PubMed]
10. Griffin, D.E. The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. Viruses
2016, 8, 282. [CrossRef] [PubMed]
11. Minor, P.D. Live attenuated vaccines: Historical successes and current challenges. Virology 2015, 479–480,
379–392. [CrossRef] [PubMed]
12. Mohsen, M.O.; Zha, L.; Cabral-Miranda, G.; Bachmann, M.F. Major findings and recent advances in virus-like
particle (VLP)-based vaccines. Semin. Immunol. 2017, 34, 123–132. [CrossRef] [PubMed]
13. Kirnbauer, R.; Taub, J.; Greenstone, H.; Roden, R.; Durst, M.; Gissmann, L.; Lowy, D.R.; Schiller, J.T. Efficient
self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 1993, 67,
6929–6936. [PubMed]
14. Wagner, R.; Teeuwsen, V.J.; Deml, L.; Notka, F.; Haaksma, A.G.; Jhagjhoorsingh, S.S.; Niphuis, H.; Wolf, H.;
Heeney, J.L. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle
HIV vaccines in the absence of protection from SHIV infection. Virology 1998, 245, 65–74. [CrossRef]
[PubMed]
15. Pereyra, F.; Jia, X.; McLaren, P.J.; Telenti, A.; de Bakker, P.I.; Walker, B.D.; Ripke, S.; Brumme, C.J.; Pulit, S.L.;
Carrington, M.; et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science 2010, 330, 1551–1557. [PubMed]
16. Andersson, A.C.; Ragonnaud, E.; Seaton, K.E.; Sawant, S.; Folgori, A.; Colloca, S.; Labranche, C.;
Montefiori, D.C.; Tomaras, G.D.; Holst, P.J. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed
virus encoded virus-like particle immunizations. Vaccine 2016, 34, 5344–5351. [CrossRef] [PubMed]
17. Leneghan, D.B.; Miura, K.; Taylor, I.J.; Li, Y.; Jin, J.; Brune, K.D.; Bachmann, M.F.; Howarth, M.;
Long, C.A.; Biswas, S. Nanoassembly routes stimulate conflicting antibody quantity and quality for
transmission-blocking malaria vaccines. Sci. Rep. 2017, 7, 3811. [CrossRef] [PubMed]
18. Thrane, S.; Janitzek, C.M.; Matondo, S.; Resende, M.; Gustavsson, T.; Jongh, W.A.; Clemmensen, S.;
Roeffen, W.; Vegte-Bolmer, M.; Gemert, G.J.; et al. Bacterial superglue enables easy development of efficient
virus-like particle based vaccines. J. Nanobiotechnol. 2016, 14, 30. [CrossRef] [PubMed]
19. Huber, B.; Schellenbacher, C.; Shafti-Keramat, S.; Jindra, C.; Christensen, N.; Kirnbauer, R. Chimeric L2-Based
Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS ONE 2017,
12, e0169533. [CrossRef] [PubMed]
20. Calazans, A.; Boggiano, C.; Lindsay, R. A DNA inducing VLP vaccine designed for HIV and tested in mice.
PLoS ONE 2017, 12, e0183803. [CrossRef] [PubMed]
21. Pinto, L.A.; Edwards, J.; Castle, P.E.; Harro, C.D.; Lowy, D.R.; Schiller, J.T.; Wallace, D.; Kopp, W.;
Adelsberger, J.W.; Baseler, M.W.; et al. Cellular immune responses to human papillomavirus (HPV)-16 L1
in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 2003, 188,
327–338. [CrossRef] [PubMed]
Vaccines 2018, 6, 10 13 of 17
22. Bayer, W.; Tenbusch, M.; Lietz, R.; Johrden, L.; Schimmer, S.; Uberla, K.; Dittmer, U.; Wildner, O. Vaccination
with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing
antibody and CD4+ T-cell responses and confers enhanced protection. J. Virol. 2010, 84, 1967–1976. [CrossRef]
[PubMed]
23. Andersson, A.C.; Holst, P.J. Increased T cell breadth and antibody response elicited in prime-boost regimen
by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice. J. Transl. Med. 2016, 14, 343.
[CrossRef] [PubMed]
24. Cimica, V.; Galarza, J.M. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin. Immunol.
2017, 183, 99–108. [CrossRef] [PubMed]
25. Fougeroux, C.; Holst, P.J. Future Prospects for the Development of Cost-Effective Adenovirus Vaccines. Int. J.
Mol. Sci. 2017, 18, 686. [CrossRef] [PubMed]
26. Colloca, S.; Barnes, E.; Folgori, A.; Ammendola, V.; Capone, S.; Cirillo, A.; Siani, L.; Naddeo, M.; Grazioli, F.;
Esposito, M.L.; et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent
cellular immunity across multiple species. Sci. Transl. Med. 2012, 4, 115ra2. [CrossRef] [PubMed]
27. Johnson, M.J.; Petrovas, C.; Yamamoto, T.; Lindsay, R.W.; Lore, K.; Gall, J.G.; Gostick, E.; Lefebvre, F.;
Cameron, M.J.; Price, D.A.; et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects
on T cell immunogenicity. J. Immunol. 2012, 188, 6109–6118. [CrossRef] [PubMed]
28. Karasavvas, N.; Billings, E.; Rao, M.; Williams, C.; Zolla-Pazner, S.; Bailer, R.T.; Koup, R.A.; Madnote, S.;
Arworn, D.; Shen, X.; et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies
that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retrovir. 2012, 28, 1444–1457.
[CrossRef] [PubMed]
29. Amara, R.R.; Villinger, F.; Altman, J.D.; Lydy, S.L.; O’Neil, S.P.; Staprans, S.I.; Montefiori, D.C.; Xu, Y.;
Herndon, J.G.; Wyatt, L.S.; et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein
DNA/MVA vaccine. Science 2001, 292, 69–74. [CrossRef] [PubMed]
30. Goepfert, P.A.; Elizaga, M.L.; Seaton, K.; Tomaras, G.D.; Montefiori, D.C.; Sato, A.; Hural, J.; Derosa, S.C.;
Kalams, S.A.; McElrath, M.J.; et al. Specificity and 6-Month Durability of Immune Responses Induced by
DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. J. Infect.
Dis. 2014, 210, 99–110. [CrossRef] [PubMed]
31. Bett, A.J.; Dubey, S.A.; Mehrotra, D.V.; Guan, L.; Long, R.; Anderson, K.; Collins, K.; Gaunt, C.; Fernandez, R.;
Cole, S.; et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human
primates and humans. Vaccine 2010, 28, 7881–7889. [CrossRef] [PubMed]
32. Barouch, D.H.; Liu, J.; Li, H.; Maxfield, L.F.; Abbink, P.; Lynch, D.M.; Iampietro, M.J.; SanMiguel, A.;
Seaman, M.S.; Ferrari, G.; et al. Vaccine protection against acquisition of neutralization-resistant SIV
challenges in rhesus monkeys. Nature 2012, 482, 89–93. [CrossRef] [PubMed]
33. Ewer, K.J.; O’Hara, G.A.; Duncan, C.J.; Collins, K.A.; Sheehy, S.H.; Reyes-Sandoval, A.; Goodman, A.L.;
Edwards, N.J.; Elias, S.C.; Halstead, F.D.; et al. Protective CD8+ T-cell immunity to human malaria induced
by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 2013, 4, 2836. [CrossRef] [PubMed]
34. Chakrabarti, B.K.; Feng, Y.; Sharma, S.K.; McKee, K.; Karlsson Hedestam, G.B.; LaBranche, C.C.;
Montefiori, D.C.; Mascola, J.R.; Wyatt, R.T. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope
glycoprotein trimers in nonhuman primates. J. Virol. 2013, 87, 13239–13251. [CrossRef] [PubMed]
35. Wyatt, L.S.; Belyakov, I.M.; Earl, P.L.; Berzofsky, J.A.; Moss, B. Enhanced cell surface expression,
immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed
by a recombinant MVA. Virology 2008, 372, 260–272. [CrossRef] [PubMed]
36. Chen, J.; Kovacs, J.M.; Peng, H.; Rits-Volloch, S.; Lu, J.; Park, D.; Zablowsky, E.; Seaman, M.S.; Chen, B. HIV-1
ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
Science 2015, 349, 191–195. [CrossRef] [PubMed]
37. Cottingham, M.G.; Carroll, F.; Morris, S.J.; Turner, A.V.; Vaughan, A.M.; Kapulu, M.C.; Colloca, S.; Siani, L.;
Gilbert, S.C.; Hill, A.V. Preventing spontaneous genetic rearrangements in the transgene cassettes of
adenovirus vectors. Biotechnol. Bioeng. 2012, 109, 719–728. [CrossRef] [PubMed]
38. Chackerian, B.; Lenz, P.; Lowy, D.R.; Schiller, J.T. Determinants of autoantibody induction by conjugated
papillomavirus virus-like particles. J. Immunol. 2002, 169, 6120–6126. [CrossRef] [PubMed]
Vaccines 2018, 6, 10 14 of 17
39. Ozorowski, G.; Pallesen, J.; de Val, N.; Lyumkis, D.; Cottrell, C.A.; Torres, J.L.; Copps, J.; Stanfield, R.L.;
Cupo, A.; Pugach, P.; et al. Open and closed structures reveal allostery and pliability in the HIV-1 envelope
spike. Nature 2017, 547, 360–363. [CrossRef] [PubMed]
40. Julien, J.P.; Lee, J.H.; Ozorowski, G.; Hua, Y.; de la Peña, A.T.; de Taeye, S.W.; Nieusma, T.; Cupo, A.;
Yasmeen, A.; Golabek, M.; et al. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase
the arsenal of native-like Env immunogens. Proc. Natl. Acad. Sci. USA 2015, 112, 11947–11952. [CrossRef]
[PubMed]
41. Pitisuttithum, P.; Rerks-Ngarm, S.; Bussaratid, V.; Dhitavat, J.; Maekanantawat, W.; Pungpak, S.;
Suntharasamai, P.; Vanijanonta, S.; Nitayapan, S.; Kaewkungwal, J.; et al. Safety and reactogenicity of
canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in
Thailand. PLoS ONE 2011, 6, e27837. [CrossRef] [PubMed]
42. Sanders, R.W.; van Gils, M.J.; Derking, R.; Sok, D.; Ketas, T.J.; Burger, J.A.; Ozorowski, G.; Cupo, A.;
Simonich, C.; Goo, L.; et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like
envelope trimers. Science 2015, 349, aac4223. [CrossRef] [PubMed]
43. Crooks, E.T.; Tong, T.; Chakrabarti, B.; Narayan, K.; Georgiev, I.S.; Menis, S.; Huang, X.; Kulp, D.; Osawa, K.;
Muranaka, J.; et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes
Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathog. 2015, 11, e1004932.
[CrossRef] [PubMed]
44. McCoy, L.E.; van Gils, M.J.; Ozorowski, G.; Messmer, T.; Briney, B.; Voss, J.E.; Kulp, D.W.; Macauley, M.S.;
Sok, D.; Pauthner, M.; et al. Holes in the Glycan Shield of the Native HIV Envelope Are a Target of
Trimer-Elicited Neutralizing Antibodies. Cell Rep. 2016, 16, 2327–2338. [CrossRef] [PubMed]
45. Capucci, S.; Wee, E.G.; Schiffner, T.; LaBranche, C.C.; Borthwick, N.; Cupo, A.; Dodd, J.; Dean, H.;
Sattentau, Q.; Montefiori, D.; et al. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus
MVA-vectored BG505 native-like envelope trimers. PLoS ONE 2017, 12, e0181886. [CrossRef] [PubMed]
46. Zolla-Pazner, S.; DeCamp, A.; Gilbert, P.B.; Williams, C.; Yates, N.L.; Williams, W.T.; Howington, R.; Fong, Y.;
Morris, D.E.; Soderberg, K.A.; et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1
subtypes correlate with decreased risk of HIV-1 infection. PLoS ONE 2014, 9, e87572. [CrossRef] [PubMed]
47. Shen, X.; Duffy, R.; Howington, R.; Cope, A.; Sadagopal, S.; Park, H.; Pal, R.; Kwa, S.; Ding, S.; Yang, O.O.;
et al. Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239
Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in
Nonhuman Primates. J. Virol. 2015, 89, 8643–8650. [CrossRef] [PubMed]
48. Pegu, P.; Vaccari, M.; Gordon, S.; Keele, B.F.; Doster, M.; Guan, Y.; Ferrari, G.; Pal, R.; Ferrari, M.G.;
Whitney, S.; et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian
immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai
trial. J. Virol. 2013, 87, 1708–1719. [CrossRef] [PubMed]
49. Tomaras, G.D.; Plotkin, S.A. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
Immunol. Rev. 2017, 275, 245–261. [CrossRef] [PubMed]
50. Golding, H.; Khurana, S.; Zaitseva, M. What Is the Predictive Value of Animal Models for Vaccine Efficacy
in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.
Cold Spring Harb. Perspect. Biol. 2017. [CrossRef] [PubMed]
51. Li, H.; Wang, S.; Kong, R.; Ding, W.; Lee, F.H.; Parker, Z.; Kim, E.; Learn, G.H.; Hahn, P.; Policicchio, B.; et al.
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and
replication in rhesus macaques. Proc. Natl. Acad. Sci. USA 2016, 113, E3413–E3422. [CrossRef] [PubMed]
52. Andersson, A.C.; Resende, M.; Salanti, A.; Nielsen, M.A.; Holst, P.J. Novel adenovirus encoded virus-like
particles displaying the placental malaria associated VAR2CSA antigen. Vaccine 2017, 35, 1140–1147.
[CrossRef] [PubMed]
53. Hviid, L.; Salanti, A. VAR2CSA and protective immunity against pregnancy-associated Plasmodium
falciparum malaria. Parasitology 2007, 134, 1871–1876. [CrossRef] [PubMed]
Vaccines 2018, 6, 10 15 of 17
54. Khan, F.; Porter, M.; Schwenk, R.; DeBot, M.; Saudan, P.; Dutta, S. Head-to-Head Comparison of Soluble vs.
Qbeta VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
PLoS ONE 2015, 10, e0142035. [CrossRef] [PubMed]
55. Storcksdieck genannt, B.M.; Niezold, T.; Temchura, V.; Pissani, F.; Ehrhardt, K.; Brown, E.P.; Osei-Owusu, N.Y.;
Hannaman, D.; Hengel, H.; Ackerman, M.E.; et al. Enhancing the Quality of Antibodies to HIV-1 Envelope
by GagPol-Specific Th Cells. J. Immunol. 2015, 195, 4861–4872. [CrossRef] [PubMed]
56. Sharma, S.K.; de, V.N.; Bale, S.; Guenaga, J.; Tran, K.; Feng, Y.; Dubrovskaya, V.; Ward, A.B.; Wyatt, R.T.
Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design.
Cell Rep. 2015, 11, 539–550. [CrossRef] [PubMed]
57. Zhao, J.; Lai, L.; Amara, R.R.; Montefiori, D.C.; Villinger, F.; Chennareddi, L.; Wyatt, L.S.; Moss, B.;
Robinson, H.L. Preclinical studies of human immunodeficiency virus/AIDS vaccines: Inverse correlation
between avidity of anti-Env antibodies and peak postchallenge viremia. J. Virol. 2009, 83, 4102–4111.
[CrossRef] [PubMed]
58. Dugast, A.S.; Chan, Y.; Hoffner, M.; Licht, A.; Nkolola, J.; Li, H.; Streeck, H.; Suscovich, T.J.;
Ghebremichael, M.; Ackerman, M.E.; et al. Lack of protection following passive transfer of polyclonal
highly functional low-dose non-neutralizing antibodies. PLoS ONE 2014, 9, e97229. [CrossRef] [PubMed]
59. Page, M.; Stebbings, R.; Berry, N.; Hull, R.; Ferguson, D.; Davis, L.; Duffy, L.; Elsley, W.; Hall, J.; Ham, C.;
et al. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the
absence of cross neutralising antibodies in a macaque model. Retrovirology 2012, 9, 56. [CrossRef] [PubMed]
60. Tuero, I.; Mohanram, V.; Musich, T.; Miller, L.; Vargas-Inchaustegui, D.A.; Demberg, T.; Venzon, D.; Kalisz, I.;
Kalyanaraman, V.S.; Pal, R.; et al. Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated
Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. PLoS Pathog. 2015, 11,
e1005101. [CrossRef] [PubMed]
61. Lee, F.H.; Mason, R.; Welles, H.; Learn, G.H.; Keele, B.F.; Roederer, M.; Bar, K.J. Breakthrough Virus
Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian
Immunodeficiency Virus Vaccine Challenge Study. J. Virol. 2015, 89, 12388–12400. [CrossRef] [PubMed]
62. Veillette, M.; Coutu, M.; Richard, J.; Batraville, L.A.; Dagher, O.; Bernard, N.; Tremblay, C.;
Kaufmann, D.E.; Roger, M.; Finzi, A. The HIV-1 gp120 CD4-bound conformation is preferentially targeted
by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals.
J. Virol. 2015, 89, 545–551. [CrossRef] [PubMed]
63. Kannanganat, S.; Nigam, P.; Velu, V.; Earl, P.L.; Lai, L.; Chennareddi, L.; Lawson, B.; Wilson, R.L.;
Montefiori, D.C.; Kozlowski, P.A.; et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular
immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J. Immunol. 2010,
185, 7262–7273. [CrossRef] [PubMed]
64. Lai, L.; Kwa, S.F.; Kozlowski, P.A.; Montefiori, D.C.; Nolen, T.L.; Hudgens, M.G.; Johnson, W.E.; Ferrari, G.;
Hirsch, V.M.; Felber, B.K.; et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention
of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012, 30,
1737–1745. [CrossRef] [PubMed]
65. Wyatt, L.S.; Earl, P.L.; Vogt, J.; Eller, L.A.; Chandran, D.; Liu, J.; Robinson, H.L.; Moss, B. Correlation
of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV
vaccines. Vaccine 2008, 26, 486–493. [CrossRef] [PubMed]
66. Baur, K.; Brinkmann, K.; Schweneker, M.; Patzold, J.; Meisinger-Henschel, C.; Hermann, J.; Steigerwald, R.;
Chaplin, P.; Suter, M.; Hausmann, J. Immediate-early expression of a recombinant antigen by modified
vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and
memory CD8 T-cell responses. J. Virol. 2010, 84, 8743–8752. [CrossRef] [PubMed]
67. Brown, S.A.; Surman, S.L.; Sealy, R.; Jones, B.G.; Slobod, K.S.; Branum, K.; Lockey, T.D.; Howlett, N.;
Freiden, P.; Flynn, P.; et al. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and
Clinical Trials. Viruses 2010, 2, 435–467. [CrossRef] [PubMed]
Vaccines 2018, 6, 10 16 of 17
68. Stephenson, K.E.; Li, H.; Walker, B.D.; Michael, N.L.; Barouch, D.H. Gag-Specific Cellular Immunity
Determines In Vitro Viral Inhibition and In Vivo Virologic Control Following SIV Challenges of Vaccinated
Rhesus Monkeys. J. Virol. 2012, 86, 9583–9589. [CrossRef] [PubMed]
69. Janes, H.; Friedrich, D.P.; Krambrink, A.; Smith, R.J.; Kallas, E.G.; Horton, H.; Casimiro, D.R.; Carrington, M.;
Geraghty, D.E.; Gilbert, P.B.; et al. Vaccine-induced gag-specific T cells are associated with reduced viremia
after HIV-1 infection. J. Infect. Dis. 2013, 208, 1231–1239. [CrossRef] [PubMed]
70. Mudd, P.A.; Martins, M.A.; Ericsen, A.J.; Tully, D.C.; Power, K.A.; Bean, A.T.; Piaskowski, S.M.; Duan, L.;
Seese, A.; Gladden, A.D.; et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012,
491, 129–133. [CrossRef] [PubMed]
71. Liu, Y.; Rao, U.; McClure, J.; Konopa, P.; Manocheewa, S.; Kim, M.; Chen, L.; Troyer, R.M.; Tebit, D.M.;
Holte, S.; et al. Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120
proteins on viral replication in different genetic backgrounds. PLoS ONE 2014, 9, e94240. [CrossRef]
[PubMed]
72. Kaufman, D.R.; Li, F.; Cruz, A.N.; Self, S.G.; Barouch, D.H. Focus and breadth of cellular immune responses
elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine 2012, 30, 506–509.
[CrossRef] [PubMed]
73. Bauer, A.; Podola, L.; Mann, P.; Missanga, M.; Haule, A.; Sudi, L.; Nilsson, C.; Kaluwa, B.; Lueer, C.;
Mwakatima, M.; et al. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous
DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen. J. Virol. 2017, 91, e00730-17.
[CrossRef] [PubMed]
74. Walsh, S.R.; Moodie, Z.; Fiore-Gartland, A.J.; Morgan, C.; Wilck, M.B.; Hammer, S.M.; Buchbinder, S.P.;
Kalams, S.A.; Goepfert, P.A.; Mulligan, M.J.; et al. Vaccination With Heterologous HIV-1 Envelope Sequences
and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
J. Infect. Dis. 2016, 213, 541–550. [CrossRef] [PubMed]
75. Ragonnaud, E.; Pedersen, A.G.; Holst, P.J. Breadth of T cell responses after immunization with adenovirus
vectors encoding ancestral antigens or polyvalent papillomavirus antigens. Scand. J. Immunol. 2017, 85,
182–190. [CrossRef] [PubMed]
76. Mothe, B.; Hu, X.; Llano, A.; Rosati, M.; Olvera, A.; Kulkarni, V.; Valentin, A.; Alicea, C.; Pilkington, G.R.;
Sardesai, N.Y.; et al. A human immune data-informed vaccine concept elicits strong and broad T-cell
specificities associated with HIV-1 control in mice and macaques. J. Transl. Med. 2015, 13, 60. [CrossRef]
[PubMed]
77. Storcksdieck genannt, B.M.; Niezold, T.; Hannaman, D.; Uberla, K.; Tenbusch, M. The improved antibody
response against HIV-1 after a vaccination based on intrastructural help is complemented by functional
CD8+ T cell responses. Vaccine 2016, 34, 1744–1751. [CrossRef] [PubMed]
78. Hancock, G.; Yang, H.; Yorke, E.; Wainwright, E.; Bourne, V.; Frisbee, A.; Payne, T.L.; Berrong, M.; Ferrari, G.;
Chopera, D.; et al. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection
and post-vaccination immune responses. PLoS Pathog. 2015, 11, e1004658. [CrossRef] [PubMed]
79. Monaco, D.C.; Dilernia, D.A.; Fiore-Gartland, A.; Yu, T.; Prince, J.L.; Dennis, K.K.; Qin, K.; Schaefer, M.;
Claiborne, D.T.; Kilembe, W.; et al. Balance between transmitted HLA preadapted and nonassociated
polymorphisms is a major determinant of HIV-1 disease progression. J. Exp. Med. 2016, 213, 2049–2063.
[CrossRef] [PubMed]
80. Kulkarni, V.; Valentin, A.; Rosati, M.; Alicea, C.; Singh, A.K.; Jalah, R.; Broderick, K.E.; Sardesai, N.Y.; Le, G.S.;
Mothe, B.; et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element
DNA vaccination in macaques. PLoS ONE 2014, 9, e86254. [CrossRef] [PubMed]
81. Kron, M.W.; Engler, T.; Schmidt, E.; Schirmbeck, R.; Kochanek, S.; Kreppel, F. High-capacity adenoviral
vectors circumvent the limitations of DeltaE1 and DeltaE1/DeltaE3 adenovirus vectors to induce
multispecific transgene product-directed CD8 T-cell responses. J. Gene Med. 2011, 13, 648–657. [CrossRef]
[PubMed]
82. Schirmbeck, R.; Reimann, J.; Kochanek, S.; Kreppel, F. The Immunogenicity of Adenovirus Vectors Limits
the Multispecificity of CD8 T-cell Responses to Vector-encoded Transgenic Antigens. Mol. Ther. 2008, 16,
1609–1616. [CrossRef] [PubMed]
Vaccines 2018, 6, 10 17 of 17
83. Betts, M.R.; Yusim, K.; Koup, R.A. Optimal antigens for HIV vaccines based on CD8+ T response, protein
length, and sequence variability. DNA Cell Biol. 2002, 21, 665–670. [CrossRef] [PubMed]
84. Masemola, A.; Mashishi, T.; Khoury, G.; Mohube, P.; Mokgotho, P.; Vardas, E.; Colvin, M.; Zijenah, L.;
Katzenstein, D.; Musonda, R.; et al. Hierarchical targeting of subtype C human immunodeficiency virus type
1 proteins by CD8+ T cells: Correlation with viral load. J. Virol. 2004, 78, 3233–3243. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
